. Erratum: Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study. J Clin Oncol 2023 Jul 14:JCO2301377. doi: 10.1200/JCO.23.01377.
PMID: 37450783